WOBURN, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences:
BMO 2024 Oncology Summit
Date: Tuesday, October 8, 2024
3rd Annual Roth Healthcare Opportunities Conference
Date: Wednesday, October 9, 2024
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$7.60 |
| Daily Change: | -0.12 -1.56 |
| Daily Volume: | 496,739 |
| Market Cap: | US$584.510M |
February 12, 2025 January 21, 2025 November 25, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
